arfolitixorin
Small moleculeexperimental
5,10-Methylenetetrahydrofolate (N5,N10-Methylenetetrahydrofolate; 5,10-CH2-THF) is cofactor in several biochemical reactions. It exists in nature as the diastereoisomer [6R]-5,10-methylene-THF. — Wikipedia
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02244632)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc(=O)c2c([nH]1)NCC1CN(c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)CN21- Mol. weight
- 457.45 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- Wikipedia5,10-Methylenetetrahydrofolate ↗
- ChEMBLCHEMBL1234270 ↗
- ChEMBLCHEMBL117348 ↗
Also known as
- 6r-mthf
- 6r-mthf
- folitixorin
- folitixorin
- modufolin
- modufolin
- modufolin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04126655 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Isofol Medical AB, Vastra Gotaland Region |
| NCT03750786 | Phase 3 | Dec 18, 2018 | Isofol Medical AB, Universidad Autonoma de Barcelona |
| NCT03203564 | Phase 1 | Jul 1, 2017 | Isofol Medical AB |
| NCT02244632 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2014 | Isofol Medical AB, University of Gothenburg |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Isofol Medical AB | For profit | 4 | 3 | 3 | 2014 |
| Universidad Autonoma de Barcelona | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Gothenburg | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Vastra Gotaland Region | Government | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1